Stem cell therapy for hip | Mayo Clinic Connect

@kdukes52, there are several discussions about stem cell therapy in the Bones, Joints & Muscles group. Here are a few you may wish to review:

Stem Cell Therapy for Rotator Cuff Tears https://connect.mayoclinic.org/discussion/stem-cell-therapy-for-rotator-cuff-tears/ Stem Cell Therapy for Arthritic Knees https://connect.mayoclinic.org/discussion/stem-cell-therapy-for-arthritic-knees/ Has anyone used PRP or Stem Cell Therapy to fix cervical discs https://connect.mayoclinic.org/discussion/has-anyone-used-prp-or-stem-cell-therapy-to-fix-cervical-discs/

While these discussions are not specific to regenerative medicine for the hip, I think you'll find a lot of relevant and related information. I'm also tagging fellow members @gailb @cobweb and @winning to join this discussion.

It is so important to do your homework and due diligence when researching new treatment options. Stem cells offer a lot of hope. But where these is hope, there is hype and charlatans as this FDA warning illustrates: FDA acts to remove unproven, potentially harmful treatment used in stem cell centers targeting vulnerable patients https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm573427.htm

You can read more about stem cells on the FDAs website here: https://www.fda.gov/AboutFDA/Transparency/Basics/ucm194655.htm

Another service I encourage you to take advantage of is Mayo Clinics Regenerative Medicine free Consult Service. If you call them, you will talk to a live person who will provide more information, research, and advice on seeking stem cell therapy from reputable providers, even if that provider is not Mayo Clinic. Their primary goal is to educate and help you find effective treatment.

Furthermore, you can add your name to a database to be notified when additional studies and information become available. Heres more information about the stem cell Consult Service http://www.mayo.edu/research/centers-programs/center-regenerative-medicine/patient-care/clinical-services/regenerative-medicine-consult-service. Or simply call 1-844-276-2003 to speak with one of our experts.

Phew, that's a long-winded response to your simple question Kdukes. Are you considering a hip replacement?

Jump to this post

Here is the original post:
Stem cell therapy for hip | Mayo Clinic Connect

Cell Therapy Processing Market to Reach US$ 11.5 Billion …

May 08, 2019 (Heraldkeeper via COMTEX) -- New York, May 08, 2019: Market Research Engine has published a new report titled as" Cell Therapy Processing Market Size By Process (Cell Processing , Cell Preservation, Distribution, and Handling , Process Monitoring and Quality Control), By Product Type (Equipment , Systems & Software , Consumables), By End User (Life Science Research Companies, Research Institutes), By Cell Type (Human Cells , Animal Cells), By Region (North America, Europe, Asia-Pacific, Rest of the World), Market Analysis Report, Forecast 2018-2024".

The global Cell Therapy Processing market is expected to exceed more than US$ 11.5 Billion by 2024, at a CAGR of 16.2% in the given forecast period.

Cell therapy is the therapeutic application of cells despite cell kind or clinical indication - a platform technology. Regenerative drugs is an approach to treating patients and so definitely not a platform technology. It's nearest to a hospital specialty, for example, medicine, medical specialty or palliative drugs, in alternative words platform technology independent. Its goals are ultimately to cure and so a paradigm shift away from typical symptom management and pain management. While its true that some cell therapies are regenerative, the bulk are not. Even as regenerative drugs is much larger than regenerative cell therapies alone, cell therapies collectively represent a market opportunity several orders of magnitude bigger than regenerative drugs. Equating one with the other is therefore not advantageous however instead will each a major disservice.

Browse Full Report: https://www.marketresearchengine.com/cell-therapy-processing-market

Market Insights

The global Cell Therapy Processing market is segregated on the basis of Process as Cell Processing, Cell Preservation, Distribution, and Handling, and Process Monitoring and Quality Control. Based on Product Type the global Cell Therapy Processing market is segmented in Equipment, 1 Cell Processing Equipment, 2 Single-Use Equipment, 3 Other Equipment, Systems & Software, and Consumables. Based on End User the global Cell Therapy Processing market is segmented in Life Science Research Companies and Research Institutes.

Based on Cell Type, the global Cell Therapy Processing market is segmented in Human Cells, 1 Stem Cells, 2 Differentiated Cells, and Animal Cells.

The global Cell Therapy Processing market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Cell Therapy Processing market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Stemcell Technologies, Miltenyi Biotec GmbH, Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius, Merck KGaA, Lonza Group, Thermo Fisher Scientific, Inc., Terumo Bct, Inc, and others are among the major players in the global Cell Therapy Processing market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Cell Therapy Processing Market has been segmented as below:

Cell Therapy Processing Market, By Process

Cell Therapy Processing Market, By Product Type

Cell Therapy Processing Market, By End User

Cell Therapy Processing Market, By Cell Type

Cell Therapy Processing Market, By Region

Cell Therapy Processing Market, By Company

The report covers:

Report Scope

The global Cell Therapy Processing market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Cell Therapy Processing market share. Major industry players with significant revenue share include Stemcell Technologies, Miltenyi Biotec GmbH , Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius , Merck KGaA, , Lonza Group , Thermo Fisher Scientific, Inc., Terumo Bct, Inc, and others.

Reasons to Buy this Report:

Customization

Customized report as per the requirement can be offered with appropriate recommendations

Request Sample Report from here: https://www.marketresearchengine.com/cell-therapy-processing-market

Table of Contents:

Other Related Market Research Reports:

Biologics Development and Manufacturing Testing Market to Reach US$ 5 Billion by 2024

Digital Polymerase Chain Reaction Market to Reach US$ 1.5 Billion by 2025

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: john@marketresearchengine.com

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read more:
Cell Therapy Processing Market to Reach US$ 11.5 Billion ...

Embryonic Stem Cell Research and Vaccines using Fetal Tissue

To defend his recent decision on stem cell research, President Bush has compared it to the moral judgment that it may be acceptable to use a vaccine cultured in fetal tissue that ultimately came from induced abortions. The President's analogy is invalid because it blurs together two very different questions arising from the use of fetal tissue in medical research:

Should a government agency or private company use tissue from induced abortions for vaccine development or other research? The Catholic bishops have answered in the negative. Such use tends to legitimize abortion as a source of "life-affirming" treatments, and requires collaboration with the abortion industry, which should be avoided. This judgment is reflected in policies governing Catholic health care. See Ethical and Religious Directives for Catholic Health Care Services (4th edition, 2001): "Catholic health care institutions need to be concerned about the danger of scandal in any association with abortion providers" (Directive 45), and "Catholic health care institutions should not make use of human tissue obtained by direct abortions even for research and therapeutic purposes" (Directive 66).

If such collaboration with abortion has already taken place, and the only vaccine made available for serious diseases contains material that was cultured in fetal tissue from an abortion, may Catholics -- out of concern for their own health or that of their children or the community submit to this vaccine without committing serious sin? Most Catholic moralists have replied in the affirmative. The recipient of the vaccine took no part in decisions to base the vaccine on this morally unacceptable source, but is coping with the results of immoral decisions made by others.

It is invalid to cite moral opinions about question (2) to avoid the moral problem posed by question (1). The federal government is choosing here and now to cooperate with researchers who have destroyed human embryos, and even in some cases to reward them with research grants (since these researchers have the most immediate access to the cell lines thereby created).

Moreover, the link between the government's actions and the destruction of human embryos is even closer here than in the case of vaccine companies using fetal tissue from abortions, because in the present case the taking of human life was done precisely in order to provide cells for research (and in some cases precisely to qualify for federal research grants).

If treatments ultimately result from this decision, Catholics will face a new form of question (2): Whether in conscience they can accept such treatments that rely on the destruction of human life. Here the moral dilemma will be even more difficult, because in this case human life was destroyed specifically to obtain these cells for research and treatment. Use of embryonic stem cells in successful treatments will increase the demand for future destruction of embryos to provide an adequate supply of tissue for thousands or millions of patients. That will pose a new and serious moral dilemma for pro-life Americans who suffer from serious diseases.

View post:
Embryonic Stem Cell Research and Vaccines using Fetal Tissue

Somatic Stem Cells and Cancer – Stem Cell Centers …

Can some somatic stem cells in our bodies be the source of common cancers? The Department of Health weighs in: So-called cancer stem cells are cancer cells that have stem cell-like properties, i.e., they can self-renew and differentiate into other cell types. They are associated with some, but not all, types of cancers.

Data suggest that recurrence of some cancers is caused by a failure of current therapies to target and kill these cancer stem cells. However, the relationship between cancer stem cells and somatic stem cells is unclear.

Somatic stem cells can become cancerous, but cancer stem cells do not necessarily come from somatic stem cells.

The similarities between somatic stem cells and cancer cells is so close (including the fundamental abilities to self-renew and differentiate) have led many to believe that cancers are caused by transforming mutations that happen in tissue-specific stem cells. One of the reasons this theory has been given some attention is because among all cancer cells within a particular tumor, only a very small cell fraction has the limited potential to regenerate the entire tumor cell population. Thus, these cells with stem-like properties have been termed cancer stem cells. Cancer stem cells can begin from mutation in normal somatic stem cells that stop controlling their physiological programs.

The stem cell theory of cancer proposes that among all cancerous cells, a few act as stem cells that reproduce themselves and sustain the cancer, much like normal stem cells normally renew and sustain our organs and tissues. In this view, cancer cells that are not stem cells can cause problems, but they cannot sustain an attack on our bodies over the long term, Stanford Medical said.

Over the years, there have been many theories about the origins of cancer. Truth be told, we still dont have all the answers on why some cancers come to be. However, one theory that is largely accepted postulates that: the growth of tissues and the reproduction of cells in our bodies are carefully regulated through the action of key sets of DNA instructions. When those DNA sequences are disruptedwhether through viruses, environmental causes like radiation or toxins, mutations transcription errors or inborn genetic flawscell reproduction becomes less well regulated. Eventually, those changes can produce the rapidly reproducing, self-protective and opportunistic cells that typify cancer, Stanford Medicine writes.

According to the American Cancer Society, men have a 39.66 percent chance, or one in three risk, of developing cancer over a lifetime. For women, the odds are slightly lower, at 37.65 percent.

The National Institute of Health states, Data from 2007 suggest that approximately 1.4 million men and women in the U.S. population are likely to be diagnosed with cancer and approximately 566,000 American adults are likely to die from cancer in 2008.

Stem cell transplants are commonly used today to help patients that have had blood-forming stem cells depleted after high doses of chemotherapy and/or radiation. Blood forming stem cells are a vital part of health because they grow and become varying types of blood cells that your body needs such as:

For your body to be healthy, all three blood cell types play a role.

Ideal candidates for stem cell therapy include those that are suffering from pain or dysfunction due to injury or age-related joint issues. If you are you worried that surgery, a lifelong dependency on pain medications, or a departure from your prior functionality are your only options, stem cell therapy may be for you.

Find out if you are a candidate for this revolutionary treatment by scheduling a free consultation with a stem cell therapist near you! If you have questions, or would like to know more about regenerative stem cell therapy, please call us at (877) 808-0016 or click contact us.

Visit link:
Somatic Stem Cells and Cancer - Stem Cell Centers ...

What is Cell Therapy | Cell Therapy Explained

In recent years, stem cells have often been portrayed by the news & media as a new wonder therapy that could regenerate virtually any damaged organs and tissues in the human body. But are stem cells really a new discovery and what is their impact in medicine?

Contrary to popular belief, its been understood for millennia that different organs have regenerative potential. The Greek poet, Hesiod, recognised this ability in the liver over 2800 years ago when he wrote about the legend of Prometheus. Such observations prove true in our modern era when the liver can regenerate even after 70% of it is has been surgically removed. This process is now attributed to the presence of stem cells in this organ. However, it wasnt until 1868 that the term stem cell was first used when the German scientist, Ernst Haechel, was studying evolution in multiple species including crustaceans. In his native language, he called it the stammzelle (stem cell in English) and he recognised the unique capability of these cells: namely, to replicate and make more stem cells whilst also being able to produce differentiated cell types, such as heart, liver and blood cells.

Such stem cells found in organs of the adult body are known as adult stem cells. Perhaps the most well studied of the adult stem cells are blood (or haematopoietic) stem cells. In the 1960s it was recognised that a blood transfusion from a healthy donor could restore the wellbeing of someone exposed to harmful levels of radiation. Many of these findings were precipitated following the horrific radiation injuries in civilian populations after atomic bombs were dropped on in Hiroshima and Nagasaki. Now blood transfusion is commonly-used to help the recovery of patients undergoing treatment for cancer. This is because the chemo- and radio-therapy used damages their own blood stem cells, which are replaced by an infusion of healthy stem cells from a suitable donor. Indeed, pioneering work in the field of blood transfusion led to Peter Medwar being awarded the Nobel Prize in Medicine in 1960. Other adult stem cells being investigated as therapies include those in skin (for treatment of burns), cornea (for repairing damage to the eye) and brain (for injuries such as stroke).

In parallel to the discoveries being made in adult stem cell research, work was starting with a different class of stem cells, known as the embryonic stem cells. During the 1960s and 70s, scientists found that testicular cancers formed bizarre tumour masses that didnt just contain testicular material but also had hair, bone, neurons and so on. The cause of these strange tumours was identified as embryonal carcinoma cells, which are stem cells that have become mutated. A few years later in 1981, better behaved embryonic stem cells were isolated from mouse embryos. These remarkable cells could be grown in the lab for long periods of time and yet be coaxed into become virtually every cell type in the mouse (about 200 different cell types). Indeed, when implanted into early stage mouse embryos, these embryonic stem cells can contribute to every tissue of the adult mouse. The embryonic stem cells could also be genetically modified and used to make new strains of mice with specifically-engineered changes in their genome. This finding revolutionised our understanding of genetics and disease, which ultimately led to the Novel Prize in Medicine being jointly awarded to Mario Capecchi, Martin Evans and Oliver Smithies in 2007.

It took another 17 years before human embryonic stem cells (hESC) were isolated in 1998, largely because different conditions were needed to grow these cells relative to their mouse counterparts and the ethics of working with human embryos. Close regulation by government groups such as the Human Fertilisation & Embryology Authority (HFEA) make sure all work is carried out in an ethical manner. Thus, hESCs can only be produced from spare embryos donated by consenting couples undergoing in vitro fertilisation (IVF, or test-tube baby) treatment. The hESCs are often considered as master or pluripotent stem cells because they make many if not all of the cell types in the human body. Unlike in the mouse, the intention with hESCs is not to make new humans but rather to use their power to make replacement cells for sick patients. This is slow and painstaking work but the first clinical trials have begun to repair macular degeneration (eye disease) by the US company Advance Cell Technologies (ACT) with initial results expected from just a few patients in 2014.

A major breakthrough came with cloning of Dolly the Sheep in 1997 by Keith Campbell, Bill Ritchie and Ian Wilmut at the Roslin Institute in Scotland. This work disproved the central dogma that stated development was unidirectional i.e. the embryo becomes the fetus which becomes the adult. In these cloning experiments, the nucleus of a fertilised sheep egg was replaced with the nucleus from an udder cell. This reconstructed nuclear transfer embryo was transplanted into a surrogate sheep mother, which gave birth to Dolly. Since this landmark discovery, many scientists worked tirelessly to see if different somatic cells (e.g. skin cells, blood cells etc) could be converted into stem cells in the lab but without the need for nuclear transfer and fertilised eggs, which is ethically-sensitive in many countries.

The major breakthrough came in 2006 by Shinya Yamanaka in Japan. To the astonishment of the worlds scientific community, his group showed skin cells from a mouse could be reprogrammed into stem cells by adding just 4 genetic factors (Oct4, Sox2, Klf4 and cMyc), now known as the Yamanaka Factors. In 2007, Yamanaka went on to show this process also worked in human cells in a process called induced pluripotency giving rise to human induced pluripotent stem cells (hiPSC). Already, hiPSC have been used to produce retinal cells, which are being transplanted into patients with eye disease in clinical trials in Japan.

It is noteworthy that transplantation is not the only use for hiPSCs and hESCs. For example, new drugs are currently tested in animals to determine whether unwanted side effects occur in organs such as the heart, liver and brain. These cell types can be made from hESC and hiPSC, so there is growing interest by the pharmaceutical industry in reducing or replacing animals with drug testing platforms that use human stem cells instead. Furthermore, because hiPSC can be made from patients who harbour genetic disorders, an exploding area of research is to recreate these disorders in the lab in what is becoming known as disease in a dish technology. This gives new opportunities to better understand these disorders and develop novel drugs or genetic therapies. It is for these reasons that the Nobel Prize for Medicine in 2012 was awarded jointly to John Gurdon in the UK for his early work on reprogramming and to Shinya Yamanaka for his work on hiPSC.

Unequivocally, the long history of stem cells shows their potential in biomedicine and there is every indication that this utility will expand in the future. However, progressing stem cells from bench to bedside takes decades of hard, slow work, which is not so exciting for the media to present. Nevertheless, the coming years should prove to be an exciting time for stem cell research and medicine.

Link:
What is Cell Therapy | Cell Therapy Explained

Best Stem Cell Doctors in Plymouth | Stem cell hip Regeneration Hip Doctor Plymouth MI

Best Stem Cell Doctors in Plymouth | Stem cell hip Regeneration Hip Doctor Plymouth MI

http://integrativehealthmi.com/ Stem Cell Website http://integrativehealthmi.com/testim... Video Testimonials

Here's just a taste of what you'll learn at this special live educational seminar: Learn about this remarkable cutting edge healing Stem Cell Doctors in Plymouth MI, technology that can actually repair damaged tissue in the body through a painless and safe stem cell injection. (Hint: Normal drugs just mask the pain.) According to Michigan Integrative Healths chief medical officer, "Patients can experience a significant decrease in pain and improved range of motion within weeks of just one treatment." When the body heals, the pain naturally goes away. Discover how stem cell injections work... (This is really fascinating stuff!) We'll explain how they pinpoint the impaired areas, remove the swelling with powerful anti-inflammatory properties and heal them by regenerating new cells and tissue. Why this innovative therapy is helpful for degenerative arthritis, degenerative cartilage and ligaments, bone spurs, degenerative joint disease, bursitis and tendonitis. If you suffer from one of these or know someone who is in pain, this could be life-changing. Michigan Integrative Health is one of the first clinics in the area to offer this highly advanced form of therapy.

To reserve your seat at this informative seminar, click on one of the buttons on below or call (844) 644-7836 or (844) MIH-STEM. When you attend, youll receive a special reduced price consultation at the clinic to explore your stem cell therapy options.

If you are unable to attend one of these seminar dates,Stem Cell Specialists in Plymouth MI, please call to schedule a consultation or find out about the next seminar

Theresa - Livonia, MI Patient

"I had back pain, sciatica, and both knees hurt. Its been 5 weeks since I received care. My back pain and sciatica are gone. My knee pain has improved by 75%. Before care my back would hurt when I stood to wash dishes. Now I have no pain."

Rick - Shelby Township, MI Patient

"I was having grinding in my shoulders at night, severe hip problem on the left side and a joint issue in the right toe. 5 weeks after care the grinding in my shoulder is just about gone. My hip pain is completely gone. I have also had a reduction in urinary urgency that has been reduced by 80-90%." Stem cell hip Regeneration Hip Doctor Plymouth MI, Stem Cell hip Regeneration Hip Doctors in Plymouth MI, Stem Cell hip Regeneration Hip Specialists in Plymouth MI, stem cell for back pain Doctors in Plymouth MI, Stem cell doctor Back pain Plymouth MI, Stem Cell Doctor for Back Pain in Plymouth MI, Stem Cell Doctors for Back pain in Plymouth MI, Stem Cell Doctors for Neck Pain in Plymouth MI, Stem Cell Doctor Neck Pain in Plymouth MI, Stem Cell Doctor lower Back pain in Plymouth MI, Stem Cell Arm pain Doctors in Plymouth MI, Stem Cell Neck Pain Doctors in Plymouth MI, Stem Cell Back Pain Doctors in Plymouth MI, Stem Cell Knee Pain Doctors in Plymouth MI,

stem cell therapy for back pain in Plymouth MI, Stem Cell Therapy for back pain in Plymouth MI, stem cell therapy for spine degeneration Plymouth MI, stem cell therapy for spine degeneration in Plymouth MI, Stem Cell Therapy & Treatment Plymouth MI, Stem Cell Therapy and Treatments in Plymouth MI, Stem Cell Therapy Treatments in Plymouth MI, The Best Stem Cell Therapy Treatments in Plymouth MI, where Can I get Stem Cell Treatment in Plymouth MI, Stem Cell Centers in Plymouth MI, Stem Cell Center in Plymouth MI, Stem Cell Clinics in Plymouth MI, Stem Cell Clinics Plymouth MI, stem cells for back pain Plymouth MI, Stem Cells for Back Pain in Plymouth MI, Stem Cells for back pain Doctor in Plymouth MI, stem cell therapy for back pain reviews Plymouth MI, Stem cell therapy for back pain Reviews in Plymouth MI, stem cell back pain clinical trials Plymouth MI, Stem Cell Back pain Clinical Trails in Plymouth MI, stem cell for back pain reviews Plymouth MI, Stem Cell for back pain Reviews in Plymouth MI, stem cell therapy for spine degeneration Plymouth MI, Stem Cell Therapy for Spine Degeneration in Plymouth MI, stem cell therapy Plymouth MI, Stem Cell Therapy in Plymouth MI, Stem cell for pain Management in Plymouth MI, Stem Cell Doctor Plymouth MI, Stem Cell Doctors in Plymouth MI, The Best Stem Cell Doctors in Plymouth MI, Stem Cell procedure in Plymouth MI, How to find a Stem Cell Doctor in Plymouth MI, How to Find Stem Cell Doctors in Plymouth MI, cost of stem cell therapy in Plymouth MI, stem cell center Plymouth MI, stem cell shoulder Plymouth MI, cervical stem cell therapy Plymouth MI, stem cell therapy Plymouth MI, stem cell pain Plymouth MI, stem cell therapy on knees Plymouth MI, stem cell shoulder Plymouth MI, stem cell therapy Plymouth MI,

Original post:
Best Stem Cell Doctors in Plymouth | Stem cell hip Regeneration Hip Doctor Plymouth MI

Difference Between Embryonic and Somatic Stem Cells …

The key difference between embryonic and somatic stem cells is that the embryonic stem cells are pluripotent undifferentiated cells that have embryonic origin while somatic stem cells are multipotent undifferentiated cells that are of tissue and organ origin.

Stem cells are undifferentiated cells which are capable of growing into true tissues or organs. Generally, there are two major stem cell types as embryonic stem cells and adult stem cells (somatic stem cells). In the case of differentiation, embryonic stem cells can differentiate into any type of cells. In contrast, somatic stem cells can only differentiate into several tissue-specific cells. Therefore, embryonic stem cells are pluripotent while somatic stem cells are multipotent. In simple words, the ability of differentiation is high in embryonic stem cells in comparison to that of somatic stem cells.

1. Overview and Key Difference 2. What areEmbryonic Stem Cells 3. What are Somatic Stem Cells 4. Similarities BetweenEmbryonic and Somatic Stem Cells 5. Side by Side Comparison Embryonic vs Somatic Stem Cells in Tabular Form 6. Summary

Embryonic stem cells are a type of undifferentiated cells present in early stages of embryonic development. The inner cell mass of the blastocyst is made up of embryonic stem cells. These embryonic stem cells are pluripotent in nature. Thus, they can differentiate into any type of cells. The extraction of embryonic stem cells can be done from the blastocyst stage of the embryonic development for stem cell culture. Following the extraction, the cells undergo maturation and division under in vitro conditions. The embryonic stem cells are able to grow in special high nutrient media where they differentiate into the three germ layers: ectoderm, endoderm, and mesoderm.

Figure 01: Embryonic Stem Cells

In modern therapy, embryonic stem cells are valuable tools in regenerative therapy and tissue replacement following injury or disease. The diseases that use embryonic stem cell therapy at present are diabetes, neurodegenerative disorders, spinal cord, and muscular injuries.

Somatic stem cells are the stem cells present in specific tissues and organs in adults. Therefore, adult stem cells is a synonym of somatic stem cells. Thus, adult stem cells originate from mature tissues and organs. They are multipotent cells; this means they can differentiate into several types of cells, but not pluripotent like embryonic stem cells. There are different types of somatic stem cells such as hematopoietic stem cells, intestinal stem cells, endothelial stem cells, neuronal stem cells, and mesenchymal stem cells.

Figure 02: Somatic Stem Cells

During division, somatic stem cells undergo two pathways. They are symmetric division and asymmetric division. The symmetric division produces daughter cells of similar properties whereas asymmetric division produces one similar daughter cell and a different progenitor cell.

There are many uses of somatic stem cells in research. They are useful in many drug testing protocols to check the effects of particular drugs or metabolites. Moreover, somatic stem cells are useful to determine the cellular behavior of particular organs and their signaling pathways. Furthermore, scientists use somatic cells as therapy as they are able to regenerate cells when proper conditions are present.

The key difference between embryonic and somatic stem cells is their site of extraction. Blastocyst stage of the embryonic development is the site of extraction of embryonic stem cells while specific tissues are the sites of extraction of somatic stem cell. Especially, embryonic stem cells can differentiate into any type of cells. In contrast, somatic stem cells cannot differentiate into all types of cells and can only differentiate into specific types of cells based on their origin. Therefore, this is also a major difference between embryonic and somatic stem cells.

Another difference between embryonic and somatic stem cells is their cell culturing process. Cell culturing of somatic stem cells are more laborious in comparison to embryonic stem cell culture.

The below infographic presents more information on the difference between embryonic and somatic stem cells.

Stem cells are undifferentiated cells. There are two broad classes of stem cells as embryonic stem cells and somatic stem cells. In summarizing the difference between embryonic and somatic stem cells, the embryonic stem cells can differentiate into any type of cells; thus, they are pluripotent. In contrast, somatic stem cells or adult stem cells can differentiate only into specific types of cells; thus, they are multipotent. Above all, the key difference between embryonic and somatic stem cells is the site of the derivation of these cell types. Embryonic stem cells are derived from the blastocyst while somatic stem cells are derived from specific organs upon the requirement.

1. Henningson, Carl T, et al. 28. Embryonic and Adult Stem Cell Therapy.The Journal of Allergy and Clinical Immunology, U.S. National Library of Medicine, Feb. 2003, http://www.ncbi.nlm.nih.gov/pubmed/12592319.

1. Human embryonic stem cells only A : Human_embryonic_stem_cells.png: (Images: Nissim Benvenisty)derivative work: Vojtech.dostal (talk) Human_embryonic_stem_cells.png (CC BY 2.5) via Commons Wikimedia 2. Sources of new adult -cells By Murtaugh, L.C. and Kopinke, D., Pancreatic stem cells (July 11, 2008), StemBook, ed. The Stem Cell Research Community, StemBook, doi/10.3824/stembook.1.3.1, http://www.stembook.org. (CC BY 3.0) via Commons Wikimedia

Samanthi holds a B.Sc. Degree in Plant Science, M.Sc. in Molecular and Applied Microbiology, and PhD in Applied Microbiology (progressing). Her research interests include Bio-fertilizers, Plant Microbe Interactions, Molecular Microbiology, Soil Fungi, and Fungal Ecology.

Visit link:
Difference Between Embryonic and Somatic Stem Cells ...

What are the unique properties of stem cells – answers.com

Stem cells differ from other kinds of cells in the body. All stem cells-regardless of their source-have three general properties: they are capable of dividing and renewing themselves for long periods; they are unspecialized; and they can give rise to specialized cell types.

Stem cells are capable of dividing and renewing themselves for long periods. Unlike muscle cells, blood cells, or nerve cells-which do not normally replicate themselves-stem cells may replicate many times, or proliferate. A starting population of stem cells that proliferates for many months in the laboratory can yield millions of cells. If the resulting cells continue to be unspecialized, like the parent stem cells, the cells are said to be capable of long-term self-renewal.

Scientists are trying to understand two fundamental properties of stem cells that relate to their long-term self-renewal:

Discovering the answers to these questions may make it possible to understand how cell proliferation is regulated during normal embryonic development or during the abnormal cell division that leads to cancer. Such information would also enable scientists to grow embryonic and non-embryonic stem cells more efficiently in the laboratory.

The specific factors and conditions that allow stem cells to remain unspecialized are of great interest to scientists. It has taken scientists many years of trial and error to learn to derive and maintain stem cells in the laboratory without them spontaneously differentiating into specific cell types. For example, it took two decades to learn how to grow human embryonic stem cells in the laboratory following the development of conditions for growing mouse stem cells. Therefore, understanding the signals in a mature organism that cause a stem cell population to proliferate and remain unspecialized until the cells are needed. Such information is critical for scientists to be able to grow large numbers of unspecialized stem cells in the laboratory for further experimentation.

Stem cells are unspecialized. One of the fundamental properties of a stem cell is that it does not have any tissue-specific structures that allow it to perform specialized functions. For example, a stem cell cannot work with its neighbors to pump blood through the body (like a heart muscle cell), and it cannot carry oxygen molecules through the bloodstream (like a red blood cell). However, unspecialized stem cells can give rise to specialized cells, including heart muscle cells, blood cells, or nerve cells.

Stem cells can give rise to specialized cells. When unspecialized stem cells give rise to specialized cells, the process is called differentiation. While differentiating, the cell usually goes through several stages, becoming more specialized at each step. Scientists are just beginning to understand the signals inside and outside cells that trigger each stem of the differentiation process. The internal signals are controlled by a cell's genes, which are interspersed across long strands of DNA, and carry coded instructions for all cellular structures and functions. The external signals for cell differentiation include chemicals secreted by other cells, physical contact with neighboring cells, and certain molecules in the microenvironment. The interaction of signals during differentiation causes the cell's DNA to acquire epigenetic marks that restrict DNA expression in the cell and can be passed on through cell division.

Many questions about stem cell differentiation remain. For example, are the internal and external signals for cell differentiation similar for all kinds of stem cells? Can specific sets of signals be identified that promote differentiation into specific cell types? Addressing these questions may lead scientists to find new ways to control stem cell differentiation in the laboratory, thereby growing cells or tissues that can be used for specific purposes such as cell-based therapies or drug screening.

Adult stem cells typically generate the cell types of the tissue in which they reside. For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow-which is called a hematopoietic stem cell-cannot give rise to the cells of a very different tissue, such as nerve cells in the brain. Experiments over the last several years have purported to show that stem cells from one tissue may give rise to cell types of a completely different tissue. This remains an area of great debate within the research community. This controversy demonstrates the challenges of studying adult stem cells and suggests that additional research using adult stem cells is necessary to understand their full potential as future therapies.

Read more from the original source:
What are the unique properties of stem cells - answers.com

Squamous Cell Carcinoma in Dogs and Cats – Vet360

Any tumour growing within (dermal), on (epidermal) or even under the skin (subdermal) should be considered a skin tumour. Some skin tumours are benign (i.e., slow-growing, completely curable with complete resection and dont spread) while others are malignant (faster growing, invasive, sometimes incurable, and may spread to other organs). In order to classify what type of tumour you are dealing with, you will need to make a fine needle aspirate or take a biopsy A biopsy can either be incisional or excisional. Whichever course is taken, a microscopic diagnosis must always, always be obtained.

No two tumours of the same kind look the same, but very different cancers can appear similar When tumours are inflamed or infected, the underlying pathology can be masked. This information is very important. If its a cytological or incisional, this information can help guide you as the best approach to cure not only the obvious lump but also manage the precancerous lesions that surround the obvious tumour. Not all skin tumours are best removed surgically! Only very small (1 2 cm on the body or neck, and <1 cm elsewhere) should be removed by excision.

Many clients and vets try to economise by removing small lumps instead of taking the extra step this can drastically alter prognosis, by spreading tumour cells.

Although theoretically any tumour can occur in the skin, we classically think of just a few types when we say skin cancer squamous cell carcinomas (SCC), melanomas, haemangiosarcomas (HSA) and mast cell tumours (MCT).

Actinic Keratosis

Actinic keratosis (AK), also known as solar keratosis or senile keratosis, is a very common lesion occurring in susceptible humans as a result of prolonged and repeated solar exposures. The action of ultraviolet radiant energy, principally UVB, results in damage to the keratinocytes and produces single or multiple, discrete, dry, rough, adherent scaly lesions. These premalignant lesions may, in time, progress to squamous cell carcinomas.

This is very important as a warning sign and should be the first thing you teach clients about. A couple of veterinary-specific manifestations of AK are the comedones or blackheads seen on cats noses (fig 1) and dogs ventra. These lesions can be managed with protection, (fig 2) imiquimod or Photodynamic Therapy (PDT). More on these modalities later.

Squamous Cell Carcinomas

Squamous Cell Carcinomas are the classical skin tumours, caused primarily by long-term to exposure to UV-B radiation. The animals most afflicted white or part-white cats and dogs. Bull Terriers, Staffies, Pit Bulls, Bulldogs and Jack Russells are amongst the dog breeds most often affected. These ex-British breeds enjoy our long, glorious South African summer sun, and tan day after day.

UV-B radiation damages DNA and this damage is cumulative and only partially repairable or reversible. Squamous cell carcinomas can look like nothing more than non-healing crusts, pimples or scabs, or they can form large, raised, ulcerating plaques.

PROGNOSIS

It is important to treat according to the stage presented:

Primary Tumour:

T0 = no tumour

T in situ = Pre-invasive carcinoma (scale, crust)

T1 = tumour <2cm diameter, superficial or exophytic

T2 = tumour 2 5 cm diameter, OR with minimal invasion irrespective of size

T3 = tumour > 5cm diameter, or with invasion of subcutis irrespective of size

T4 = invading fascial, muscle, bone or cartilage, regardless of size

Regional lymph nodes:

N0 = no involvement

N1 = lymphnodeinvolvement

Distant metastasis:

M0 = no metastasis

M1 = evidence of metastasis

Ulceration of the primary tumour is associated with a biologically more aggressive lesion and a poorer prognosis. It is not known why ulcerated primaries have a more aggressive biologic nature. It is not likely due to underestimation of the thickness due to the ulcer crater. Ulcerated lesions tend to be thicker and have a nodular growth pattern, but the increased thickness does not account for the poorer prognosis. However, the depth or width of surface ulceration has been significantly correlated with survival. Other histologic prognosticators include the mitotic indices, whirling and the presence or absence of lymphatic or blood vessel invasion are relevant to prognosis.

Tumours in situ look like nothing more than scaly, scabby skin and offer another earlier warning sign, the best opportunity for cure, and are a wake up call. My preference for this is to use immunotherapy with imiquimod cream, or photodynamic therapy for T in situ and T1 tumours.

T2 tumours which are large but NON invasive (T2 large) also respond well to PDT or radiotherapy, but those that are T2 invasive require surgery or aggressive PDT (only to 5mm depth maximum). Once it gets to T2 invasive or T3+, cure rates using any technique drop to below 40% (from >85%) so teach your pet owners about skin cancer and early aggressive intervention from the first vaccination!

T3 and T1-4N/(any) M0/1 must be referred to a specialist for management. I see huge disasters when GPs approach these with surgery. Dogs are disfigured and then referred when they could have kept penises, mobility or faces with a proper approach from the beginning. An integrated approach using multiple modalities and an understanding of tissue tolerances, treatment sequencing and proper patient surveillance are beyond the scope of general practice. Managing such a patient is often possible, but is an 8 20 week process.

More extensive tumours may require additional surgery, chemotherapy or radiation to achieve good results. Their main importance is that they recur because skin of the ventral abdomen, ears or nose have been damaged. (fig 3) Cutting out squamous cell carcinomas can be like the little Dutch boy plugging the hole in the dyke with a finger another often just pops up elsewhere.

Recurrent SCC may require specialist attention to get under control or cure. In any event, thoracic radiographs should be performed. SCC of the feet (pedal SCC) is far more aggressive and spreads to the lungs earlier than other SCC of the skin, so always attend to any non-healing wound or lump of >1 weeks duration by having it checked using histopathology.

Treatment

Figure 1. White cat with nasal SCC this is the earliest stage the presence of discharge and slight scaling around the nose and eyelids. If treated appropriately at this stage, the prognosis for cure is close to 100%

Figure 2. UV suit UV-resistant suits (obtained from Dr Georgina Crewe), protect the healthy or precancerous skin and are an essential part of post-treatment management

Photodynamic Therapy (PDT) (fig 4) is a technique using the application or injection of photosensitising agents in different concentrations. They accumulate in certain tumours and when subjected to high-fluence (200-300 W/cm2) light of a specific frequency, keyed to the particular molecule being used, the molecules aggregate into unstable complexes that then restabilise by release of various oxygen radicals which cause lipid membrane, protein and DNA damage. Over-treatment causes regional vasoconstriction and side effects, without increase in toxicity; undertreatment achieves little, but aggravates the inflammation. This treatment is effective only in lesions <5mm thick. Treatment is once a monthly, for 1 3 treatments, depending on severity and extent. Pre-cancerous actinic keratosis can also be successfully managed using this technique.

Immunotherapy using Imiquimod (Aldara; 3M), animidazoquinolinamine, is an immune system modulator and possesses both potent antiviral and antitumor activity in animal models and humans. Current theories suggest that imiquimod acts both directly by inducing apoptosis and by inducing secretion of pro-inflammatory cytokines. Imiquimod activates macrophages and other cells via binding to cell surface receptors, such as Toll receptor 7, and thereby induces secretion of pro-inflammatory cytokines such as interferon-a (IFN-a), tumour necrosis factor-a (TNF-a), and interleukin-12 (IL- 12). These cytokines bias towards a Th1-dominant immune response, which in general is associated with inflammation and tissue injury through activated inflammatory leukocytes and with cytolytic activity through CD8+-lymphocytes (Abbas et al 1996). Imiquimod can also induce apoptosis directly in a Bcl- 2-family-dependent manner by downregulating anti-apoptotic genes such as hurpin and HAX-1.

Treatment is applied to lesions Monday to Friday, once daily, for 6 12 weeks; inflammation caused by the treatment can occasionally be severe and require NSAIDs.

I reserve this for small/early/superficial lesions in cats due to the cost of the cream. Clients must wear gloves to protect themselves. Efficacy is reported as about 75%, with a median survival time of 1189 days, although recurrent lesions do seem to respond to the therapy.

5-Fluorouracil use in animals: this drug is rapidly and fatally neurotoxic in cats even as eye drops. In dogs, the tolerance is also very low and if licked it can trigger fatal mucosal sloughing. Dont use in veterinary practice.

CRYOTHERAPY is outdated, painful, disfiguring and has a lower success rate than other therapies mentioned. Do not use this. Poor technique is a major reason for treatment failure; it requires training and experience and is potentially hazardous to the operator.

RADIATION THERAPY: the use of a linear accelerator to deliver high-voltage (4 20 MeV) electrons or photons for the treatment of surface tumours is called teletherapy. This technique has the potential for extreme harm if improperly performed, and all such cases are specialist cases and must be referred to a person with the relevant training. Theres a reason its an entire field of speciality in itself in the US and Europe. It requires a knowledge of radiation physics, radiation biology and management of radiation side effects that cannot be gleaned from a few lectures.

The role of surgery in managing skin tumours.

Surgery is an important part of management of these conditions. For some tumours e.g. BCC, HA/HSA, MCT, a properly-performed excision can be curative. In others, e.g. SCC, the surrounding skin is often also on an anaplastic march that is unstoppable by surgery alone. Surgery then helps debulk larger masses that would not respond as well to wider-field but lower-intensity therapies e.g. imiquimod, PDT, RT. The timing and planning is critical. Discuss this with a specialist BEFORE radiation or PDT PLEASE! Post-surgical fibrosis decreases the efficacy of other modalities! (fig 5)

Figure 3. SCC ear pinna removal This is the degree of surgery required for more advanced SCC of the pinna, and is to be avoided if possible, by appropriate education of the client at first vaccination of the kitten. This sort of cat may be allowed out at night, but not during the daytime.

Figure 4. PDT Patient undergoing photodynamic therapy at Inanda Vets. Basal Cell Carcinomas

Basal cell tumours are a benign tumour that look very similar to SCC, and are quite common in cats in other parts of the world. In dogs, they typically occur around the head and are not unlike canine cutaneous histiocytoma (hence the need for a tissue diagnosis). They are usually single, raised, ulcerated button-like tumours. Surgery alone is normally curative. They can be diagnosed by cytology or histopathology. BCC and SCC are classed together as the Keratinocytic Skin Cancers.

Figure 5. Multiple raised SCC on the ventrum of a dog; the previous surgeries have contributed to scar tissue formation, which makes radiation less effective, and future surgeries more difficult. The widespread nature of the disease means a novel approach must be taken if control is to be achieved. Patients arriving at this stage are major challenges to cure.

References

BERGMAN, P. J. 2007. Anticancer vaccines. Vet Clin North Am Small Anim Pract, 37, 1111-9; vi-ii.

BROCKLEY, L. K., COOPER, M. A. & BENNETT, P. F. 2013. Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival. N Z Vet J, 61, 25-31.

DANK, G., RASSNICK, K. M., SOKOLOVSKY, Y., GARRETT, L. D., POST, G. S., KITCHELL, B. E., SELLON, R. K., KLEITER, M., NORTHRUP, N. & SEGEV, G. 2012. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol, 9999.

EMANUEL, E. J. & JOFFE, S. 2003. Ethics in Oncology. In: HOLLAND, M. & FREI, E. (eds.) Cancer Medicine 6. 6th ed.: Lippincott.

GILL, V. L., BERGMAN, P. J., BAER, K. E., CRAFT, D. & LEUNG, C. 2008. Use of imiquimod 5% cream (Aldara) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002-2005). Vet Comp Oncol, 6, 55-64.

GROSENBAUGH, D. A., LEARD, A. T., BERGMAN, P. J., KLEIN, M. K., MELEO, K., SUSANECK, S., HESS., P. R., JANKOWSKI, M. H., KURZMAN, I. & WOLCHOK, J. D. 2011. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research, 72, 1631-1638.

KILLICK, D. R., STELL, A. J. & CATCHPOLE, B. 2015. Immunotherapy for canine canceris it time to go back to the future? J Small Anim Pract, 56, 229-41.

MARTIN, P. D. & ARGYLE, D. J. 2013. Advances in the management of skin cancer. Veterinary Dermatology, 24, 173-e38.

MCLEAN, J. L. & LOBETTI, R. G. 2015. Use of the melanoma vaccine in 38 dogs: The South African experience. J S Afr Vet Assoc, 86, 1246.

OTTNOD, J. M., SMEDLEY, R. C., WALSHAW, R., HAUPTMAN, J. G., KIUPEL, M. & OBRADOVICH, J. E. 2013. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol, 11, 219-29.

PETERS-KENNEDY, J., SCOTT, D. W. & MILLER, W. H., JR. 2008. Apparent clinical resolution of pinnal actinic keratoses and squamous cell carcinoma in a cat using topical imiquimod 5% cream. J Feline Med Surg, 10, 593-9.

Photos: Courtesey Inanda Vet (Dr Anthony Zambeli)

Excerpt from:
Squamous Cell Carcinoma in Dogs and Cats - Vet360

Induced pluripotent stem cells don’t increase genetic …

Called induced pluripotent stem cells (iPSCs), this technique opens the doors to medical advances, including generating cartilage cell tissue to repair knees, retinal cells to improve the vision of those with age-related macular degeneration and other eye diseases, and cardiac cells to restore damaged heart tissues.

Despite its immense promise, adoption of iPSCs in biomedical research and medicine has been slowed by concerns that these cells are prone to increased numbers of genetic mutations.

A new study by scientists at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, suggests that iPSCs do not develop more mutations than cells that are duplicated by subcloning. Subcloning is a technique where single cells are cultured individually and then grown into a cell line. The technique is similar to the iPSC except the subcloned cells are not treated with the reprogramming factors which were thought to cause mutations. The researchers published their findings on February 6, 2017, in the Proceedings of the National Academy of Sciences.

"This technology will eventually change how doctors treat diseases. These findings suggest that the question of safety shouldn't impede research using iPSC," said Pu Paul Liu, M.D., Ph.D., co-author, senior investigator in NHGRI's Translational and Functional Genomics Branch and deputy scientific director for the Division of Intramural Research.

Dr. Liu and his collaborators examined two sets of donated cells: one set from a healthy person and the second set from a person with a blood disease called familial platelet disorder. Using skin cells from the same donor, they created genetically identical copies of the cells using both the iPSC and the subcloning techniques. They then sequenced the DNA of the skin cells as well as the iPSCs and the subcloned cells and determined that mutations occurred at the same rate in cells that were reprogrammed and in cells that were subcloned.

Most genetic variants detected in the iPSCs and subclones were rare genetic variants inherited from the parent skin cells. This finding suggests that most mutations in iPSCs are not generated during the reprogramming or iPSC production phase and provides evidence that iPSCs are stable and safe to use for both basic and clinical research, Dr. Liu said.

"Based on this data, we plan to start using iPSCs to gain a deeper understanding of how diseases start and progress," said Erika Mijin Kwon, Ph.D., co-author and NHGRI post-doctoral research fellow. "We eventually hope to develop new therapies to treat patients with leukemia using their own iPSCs. We encourage other researchers to embrace the use of iPSCs."

Continue reading here:
Induced pluripotent stem cells don't increase genetic ...